Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.71
EGLT's Cash to Debt is ranked lower than
66% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. EGLT: 3.71 )
Ranked among companies with meaningful Cash to Debt only.
EGLT' s 10-Year Cash to Debt Range
Min: 0.91  Med: 10000.00 Max: No Debt
Current: 3.71
Equity to Asset 0.32
EGLT's Equity to Asset is ranked lower than
84% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. EGLT: 0.32 )
Ranked among companies with meaningful Equity to Asset only.
EGLT' s 10-Year Equity to Asset Range
Min: 0.32  Med: 0.79 Max: 0.85
Current: 0.32
0.32
0.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1933.24
EGLT's Operating margin (%) is ranked lower than
84% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -71.51 vs. EGLT: -1933.24 )
Ranked among companies with meaningful Operating margin (%) only.
EGLT' s 10-Year Operating margin (%) Range
Min: -1934.17  Med: -943.77 Max: -440.97
Current: -1933.24
-1934.17
-440.97
Net-margin (%) -1906.08
EGLT's Net-margin (%) is ranked lower than
84% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. EGLT: -1906.08 )
Ranked among companies with meaningful Net-margin (%) only.
EGLT' s 10-Year Net-margin (%) Range
Min: -2250.73  Med: -1031.47 Max: -449.46
Current: -1906.08
-2250.73
-449.46
ROE (%) -92.27
EGLT's ROE (%) is ranked lower than
78% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. EGLT: -92.27 )
Ranked among companies with meaningful ROE (%) only.
EGLT' s 10-Year ROE (%) Range
Min: -444.79  Med: -444.79 Max: -444.79
Current: -92.27
ROA (%) -63.62
EGLT's ROA (%) is ranked lower than
77% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. EGLT: -63.62 )
Ranked among companies with meaningful ROA (%) only.
EGLT' s 10-Year ROA (%) Range
Min: -155.7  Med: -140.37 Max: -106.79
Current: -63.62
-155.7
-106.79
ROC (Joel Greenblatt) (%) -1464.14
EGLT's ROC (Joel Greenblatt) (%) is ranked lower than
65% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. EGLT: -1464.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EGLT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1143.5  Med: -1062.19 Max: -685.58
Current: -1464.14
-1143.5
-685.58
» EGLT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

EGLT Guru Trades in

EGLT Guru Trades in

EGLT Guru Trades in

Q1 2014

EGLT Guru Trades in Q1 2014

Steven Cohen 31,594 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with EGLT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.63
EGLT's P/B is ranked lower than
75% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. EGLT: 7.63 )
Ranked among companies with meaningful P/B only.
EGLT' s 10-Year P/B Range
Min: 1.41  Med: 3.33 Max: 9.77
Current: 7.63
1.41
9.77
P/S 81.80
EGLT's P/S is ranked lower than
80% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 14.66 vs. EGLT: 81.80 )
Ranked among companies with meaningful P/S only.
EGLT' s 10-Year P/S Range
Min: 37.92  Med: 93.88 Max: 603
Current: 81.8
37.92
603
EV-to-EBIT -4.84
EGLT's EV-to-EBIT is ranked lower than
465% of the 225 Companies
in the Global Biotechnology industry.

( Industry Median: 29.73 vs. EGLT: -4.84 )
Ranked among companies with meaningful EV-to-EBIT only.
EGLT' s 10-Year EV-to-EBIT Range
Min: -6.7  Med: -2.80 Max: -0.3
Current: -4.84
-6.7
-0.3
Current Ratio 2.52
EGLT's Current Ratio is ranked lower than
69% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. EGLT: 2.52 )
Ranked among companies with meaningful Current Ratio only.
EGLT' s 10-Year Current Ratio Range
Min: 0.86  Med: 5.68 Max: 29.19
Current: 2.52
0.86
29.19
Quick Ratio 2.43
EGLT's Quick Ratio is ranked lower than
66% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. EGLT: 2.43 )
Ranked among companies with meaningful Quick Ratio only.
EGLT' s 10-Year Quick Ratio Range
Min: 0.86  Med: 5.68 Max: 29.19
Current: 2.43
0.86
29.19
Days Inventory 2.00
EGLT's Days Inventory is ranked higher than
93% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. EGLT: 2.00 )
Ranked among companies with meaningful Days Inventory only.
EGLT' s 10-Year Days Inventory Range
Min: 0  Med: 0.00 Max: 0
Current: 2
Days Sales Outstanding 1.00
EGLT's Days Sales Outstanding is ranked higher than
98% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. EGLT: 1.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
EGLT' s 10-Year Days Sales Outstanding Range
Min: 56.56  Med: 107.28 Max: 321.28
Current: 1
56.56
321.28

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 21.05
EGLT's Price/Net Current Asset Value is ranked lower than
84% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. EGLT: 21.05 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EGLT' s 10-Year Price/Net Current Asset Value Range
Min: 2.09  Med: 3.58 Max: 21.92
Current: 21.05
2.09
21.92
Price/Tangible Book 14.11
EGLT's Price/Tangible Book is ranked lower than
85% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. EGLT: 14.11 )
Ranked among companies with meaningful Price/Tangible Book only.
EGLT' s 10-Year Price/Tangible Book Range
Min: 1.9  Med: 3.45 Max: 14.69
Current: 14.11
1.9
14.69
Price/Median PS Value 0.88
EGLT's Price/Median PS Value is ranked higher than
57% of the 548 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. EGLT: 0.88 )
Ranked among companies with meaningful Price/Median PS Value only.
EGLT' s 10-Year Price/Median PS Value Range
Min: 0.47  Med: 0.92 Max: 4.98
Current: 0.88
0.47
4.98
Earnings Yield (Greenblatt) (%) -26.06
EGLT's Earnings Yield (Greenblatt) (%) is ranked lower than
81% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. EGLT: -26.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EGLT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -44.3  Med: 0.00 Max: 0
Current: -26.06
-44.3
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
» More Articles for EGLT

Headlines

Articles On GuruFocus.com
Wall Street’s Best and Worst Calls of the First Quarter 2015 May 07 2015 

More From Other Websites
EGALET CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Jul 02 2015
Egalet Reports Encouraging Results on Pain Drug Egalet-002 - Analyst Blog Jul 01 2015
EGALET CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 01 2015
Egalet Slumps: EGLT Falls 7.3% in Session - Tale of the Tape Jul 01 2015
Egalet to Present at Upcoming Conferences This Summer Jul 01 2015
Egalet to Present at Upcoming Conferences This Summer Jul 01 2015
EGALET CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 30 2015
Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 Jun 30 2015
Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 Jun 30 2015
EGALET CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 29 2015
Egalet Announces Positive Top-Line Results from Intranasal Human Abuse Liability Study of... Jun 29 2015
Egalet says drug less likely to be abused than other painkillers Jun 29 2015
Egalet Announces Positive Top-Line Results from Intranasal Human Abuse Liability Study of... Jun 29 2015
EGALET CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 25 2015
Egalet's Abuse-Deterrent, Extended-Release Morphine Demonstrates Bioequivalence at 60 mg Dose Jun 25 2015
Egalet's Abuse-Deterrent, Extended-Release Morphine Demonstrates Bioequivalence at 60 mg Dose Jun 25 2015
Egalet Announces Launch of Specialty Pharmaceutical Sales Force Jun 23 2015
Egalet Announces Launch of Specialty Pharmaceutical Sales Force Jun 23 2015
EGALET CORP Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements... Jun 19 2015
EGALET CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK